KENYA

CERVICAL CANCER PROFILE

Morbidity and Mortality

Crude cervical cancer incidence per 100,000 women (2020): 19.4
Age-standardized cervical cancer incidence per 100,000 women (2020): 31.3
Cumulative risk of cervical cancer, ages 0-74 (2020): 3.6%
Cervical cancer deaths (2019): 3,400
Cervical cancer mortality-to-incidence ratio (2020): 0.61
Population-based cancer registry exists (2021): Yes

Primary Prevention

HPV vaccination programme coverage among girls (2020)

Programme coverage

Coverage by age 15:

* 1 in 10 girls in the primary target cohort in 2020 have received their final HPV vaccination dose

HPV vaccination programme (2020):

HPV included in national vaccination programme: Yes
Scale of vaccination programme: National
Year of introduction: 2019
Primary target cohort: 10 years

Related risk factors:

Tobacco use prevalence, women aged 15+ years (2020): 2%
Condom use at last high-risk sex (2014): 44%
HIV incidence per 1000, women aged 15+ years (2020): 1.4

Secondary Prevention

National screening programme for cervical cancer exists (2021): Yes
Primary screening test used (2021): VIA
Target age range of programme (2021): 25-49 years
Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): Yes
Clearly defined referral system exists from primary care to secondary and tertiary care (2021): Yes

Screening for cervical cancer (2019)

Ever screened

1 in 10 women have been screened for cervical cancer in the last 5 years

Treatment and Supportive Care

National guidelines on cervical cancer management exist (2021): Yes

Cancer diagnosis and treatment services generally available (2021):
Cancer centre or cancer department at tertiary level: Yes
Pathology services (laboratories): Yes
Cancer surgery: Yes
Chemotherapy: Yes
Radiotherapy: No

Palliative care for patients with NCDs in the public health system generally available (2021):
In primary health care facilities: No
In community or home-based care: No

WHO Cervical Cancer Elimination Strategy Targets for 2030

90% of girls fully vaccinated with the HPV vaccine by the age of 15
70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
90% of women identified with cervical disease receive treatment

World Health Organization - Cervical Cancer Country Profiles, 2021